Validation of the 6 th edition AJCC pancreatic cancer staging system

  • Bilimoria K
  • Bentrem D
  • Ko C
  • et al.
N/ACitations
Citations of this article
44Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

BACKGROUND. With the development of stage-specific treatments for pancreatic cancer, controversies exist concerning optimal clinical and pathologic staging. The most recent edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual 6th Edition included some notable modifications. In anticipation of the 7th edition's publication, the authors evaluated the predictive ability of the current pancreatic adenocarcinoma staging system. METHODS. By using the National Cancer Data Base (1992-1998), 121,713 patients were identified with pancreatic adenocarcinoma. All patients were restaged by AJCC 6th edition guidelines. Stage-specific overall survival was estimated by using the Kaplan-Meier method and compared with log-rank tests. Concordance indices were calculated to evaluate the discriminatory power of the staging system. Cox modeling was used to determine the relative impact of T, N, and M classification on survival. RESULTS. For all patients, there was 5-year survival discrimination by stage (P

Cite

CITATION STYLE

APA

Bilimoria, K. Y., Bentrem, D. J., Ko, C. Y., Ritchey, J., Stewart, A. K., Winchester, D. P., & Talamonti, M. S. (2007). Validation of the 6 th edition AJCC pancreatic cancer staging system. Cancer, 110(4), 738–744. https://doi.org/10.1002/cncr.22852

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free